

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this notice, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this notice.



AIM Vaccine Co., Ltd.
艾美疫苗股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 06660)

NOTICE OF 2023 ANNUAL GENERAL MEETING

NOTICE IS HEREBY GIVEN that the 2023 annual general meeting (the “**AGM**”) of AIM Vaccine Co., Ltd. (the “**Company**”) will be held at meeting room, 10/F, Gangwu Building, No. 1 Fenghe Road, Lujiazui Street, Pudong New District, Shanghai, the PRC at 10:00 a.m. on May 20, 2024 to consider and, if thought fit, to pass with or without amendments, the following resolutions.

ORDINARY RESOLUTIONS

1. To consider and approve the report of the Directors for the year 2023.
2. To consider and approve the report of the Supervisory Committee for the year 2023.
3. To consider and approve the 2023 annual report of the Company.
4. To consider and approve the audited financial statements of the Group for the year 2023.
5. To consider and approve the profit distribution plan of the Company for the year 2023.
6. To consider and approve the final settlement of accounts of the Company for the year 2023.
7. To consider and approve the grant of authorization to the Board to approve the financial budget of the Group for the year 2024.
8. To consider and approve the re-appointment of Ernst & Young as auditors for the year 2024.

SPECIAL RESOLUTIONS

9. To grant the Board a general mandate to allot, issue or otherwise deal with new Shares not exceeding 20% of the total number of Shares in issue as at the date of passing the special resolution according to special resolution No. 9 set out in the circular of the Company dated April 26, 2024 (the “**Circular**”).
10. To grant the Board a general mandate to repurchase H Shares not exceeding 10% of the total number of H Shares in issue as at the date of passing the special resolution according to special resolution No. 10 set out in the Circular.

Details of the above resolutions are set out in the Circular. Unless otherwise stated, terms used in this notice shall have the same meanings as defined in the Circular.

By order of the Board
AIM Vaccine Co., Ltd.

Mr. Yan ZHOU

*Chairman of the Board, Executive Director and
Chief Executive Officer*

Beijing, the PRC, April 26, 2024

Notes:

1. All resolutions at the AGM will be taken by poll (except where the chairman decides to allow a resolution relating to a procedural or administrative matter to be voted on by a show of hands) pursuant to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited. The results of the poll will be published on the website of Hong Kong Exchanges and Clearing Limited (www.hkexnews.hk) and the Company's website (www.aimbio.com) after the AGM.
2. Any Shareholder entitled to attend and vote at the AGM convened by the above notice may appoint one or more proxies to attend the meeting and vote instead of him/her while voting by poll. A proxy needs not be a Shareholder of the Company.
3. To be valid, the proxy form together with the power of attorney or other authority, if any, under which it is signed, or a certified copy of such power of attorney or authority, must be completed and returned to the Company's H Share registrar, Tricor Investor Services Limited at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong, at least 24 hours before the time scheduled for holding the meeting (i.e. before 10:00 a.m. on May 19, 2024) or any adjourned meeting thereof (as the case may be). Completion and return of the form of proxy will not preclude the Shareholders of the Company from attending and voting in person at the meeting, and in such event, the instrument appointing a proxy shall be deemed to be revoked.
4. For the purpose of determining the list of H Shareholders who are entitled to attend and vote at the AGM, the register of members of the Company will be closed from May 14, 2024 to May 20, 2024, both days inclusive, during which period no transfer of Shares will be registered. In order to be eligible to attend and vote at the AGM, unregistered holders of H Shares shall ensure that all transfer documents accompanied by the relevant share certificates must be lodged with the Company's H Share registrar, Tricor Investor Services Limited at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong, before 4:30 p.m. on May 13, 2024 for transfer registration.
5. In case of joint Shareholders, the vote of the senior joint Shareholder who tenders a vote, whether in person or by proxy, will be accepted to the exclusion of the votes of the other joint Shareholder(s). For this purpose, seniority will be determined by the order in which the names stand in the H Share register of members of the Company in respect of the joint shareholding.
6. Shareholders who attend the meeting in person or by proxy shall bear their own travelling and accommodation expenses.
7. A Shareholder or his/her proxy should produce proof of identity when attending the AGM.
8. The contact details of the above meeting are:

The Office of the Board of AIM Vaccine Co., Ltd.
Address: Room 412, 4/F, Building 6, No. 105 Jinghai 3rd Road, Beijing Economic-Technological Development Area, Beijing, the PRC
Postal code: 100000
Phone: +86 10-8595 0689
Email: aim.securities@aimbio.com
9. Further details of the resolutions are set out in the Circular. Unless otherwise indicated, capitalized terms used in this notice shall have the same meanings as those defined in the Circular.
10. All dates and time in this notice refer to Hong Kong dates and time.

As at the date of this notice, the Board of Directors of the Company comprises Mr. Yan ZHOU, Mr. Wen GUAN and Mr. Shaojun JIA as executive directors; Mr. Jie ZHOU, Mr. Xin ZHOU, Mr. Jichen ZHAO and Ms. Aijun WANG as non-executive directors; and Professor Ker Wei PEI, Mr. Hui OUYANG, Ms. Jie WEN and Mr. Xiaoguang GUO as independent non-executive directors.